BELMONT, CA, USA I June 24, 2025 I Supercede Therapeutics, Inc., a startup biotech company focused on small molecule drug development, today announced ...

The scientists found that Itgb8 binds to the protein LAP. Together with LRRC33, LAP immobilizes TGF-β on the cell surface, positioning it to engage with TGF-β receptors. Both LAP and LRRC33 are ...

HO-1 inhibits the activation of the TGF-ß/Smad3 pathway in NAFLD-related liver fibrosis through SIRT1. These findings provide insights into new therapeutic strategies for treating NAFLD ...

It found that “cold” tumors, ones that haven’t yet been infiltrated by immune cells, are just as vulnerable to checkpoint inhibitors as “hot” tumors, which have been infiltrated. In mice, these cold ...

A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal ...

News PR Newswire EpicentRx's Oncolytic Virus-delivered TGFβ Inhibitor, AdAPT-001, Receives FDA Fast Track Designation for Recurrent or Refractory Soft Tissue Sarcoma Treatment ...

The new study lays the groundwork for clinical trials combining androgen receptor inhibitors with EZH2 or TGF-β inhibitors for patients with therapy-resistant prostate cancer characterized by ...

Furthermore, since TGF-β is associated with immune suppression in tumors, inhibiting this pathway could enhance immunotherapy effectiveness, a treatment with limited success against prostate ...

Furthermore, since TGF-β is associated with immune suppression in tumors, inhibiting this pathway could enhance immunotherapy effectiveness, a treatment with limited success against prostate ...

Loeys-Dietz Syndrome is a complex and multifaceted genetic disorder that requires a comprehensive and coordinated approach ...

The TGF-β pathway is essential for regulating cell growth, differentiation, and immune responses. It functions as a tumor suppressor by inhibiting cell proliferation and inducing apoptosis.

An oncolytic virus–delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment. Journal of Experimental Medicine, 2023; 220 (10) DOI: 10.1084/jem.20230053 ...